An observational study in Multiple Sclerosis, Relapsing-Remitting, sponsored by Rush University Medical Center. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-08.
Sponsored by Rush University Medical Center · Observational
Multiple sclerosis (MS) is a chronic immune central nervous system (CNS) disease of unknown cause. Recent studies suggest that gut microbiota could be a trigger for the neuro-inflammation in MS and abnormal gut microbiota composition has been reported in MS patients. These data provided scientific rationale for microbiota-directed intervention, like stool transplant, for the treatment of MS.
A subject (n-of-1) clinically diagnosed with Relapsing Remitting Multiple Sclerosis (RRMS), by Rush University Neurologists, volunteered and provided written informed consent to participate in this study conducted by Rush University Medical Center's department of Digestive Diseases and Nutrition. The RRMS subject underwent a fecal microbiota transplantation (FMT) administered outside the United States, at Taymount Clinic in the Bahamas, for the treatment of their MS. Being one of the investigators' patients, the subject volunteered to donate their stool samples to the Rush University Medical Center Gastrointestinal (GI) tissue repository for microbiota interrogation at the following time points: before FMT (baseline), 3, 13, 26, 39, 52 weeks (1 year) after FMT, to determine the impact on their microbiota composition and sustainability of the change. The subject also agreed to donate their blood during the above stated time points to see if FMT affected markers of bacteria translocation and systemic inflammation. The subject also agreed to have their GI symptoms, diet, sleep, and MS related symptoms (rating scales or questionnaires), MRI (brain \& spine), as well as their gait metric activity objectively assessed to see if the FMT affects these symptoms and whether any observed improvement is sustained, in this proof-of-concept study. Based on this research, the investigators hypothesize that the FMT will significantly altered the overall microbial community structure to promote the growth of short chain fatty acid (SCFA)-producing beneficial bacteria, which in turn could potentially improve the MS subject's health outcomes, neurological symptoms, and walking metrics over time. More clinical trials (larger sample size) will be needed to study the potential of FMT for the treatment of MS and to examine the long term effects. FMT is an emerging treatment approach for MS. The donor selection, the separation of fecal bacteria, the frequency of FMT, the way of infusion, the long-term safety, and efficacy are still uncertain and need to be examined.
3,460 studies on the registry are indexed under Multiple Sclerosis; 661 are open to participants now.
This study's enrollment of 1 is below the median of 100 across 1,016 observational studies indexed under Multiple Sclerosis.
Browse Multiple Sclerosis studies →Rush University Medical Center is the lead sponsor of 394 studies on the registry; 61 are open to participants now.
Of its 30 completed or terminated interventional studies of FDA-regulated products, 25 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
One of the investigators' patients planned to have a fecal microbiota transplant (FMT) for treatment of their MS, at the Taymount Clinic in the Bahamas, volunteered to donate multiple sample collection time points for stool and blood. Additionally, the subject would undergo gait metric activity and MRI (brain \& spine), as well as completing MS rating scales and various GI, diet and sleep clinical questionnaires.
Exclusion Criteria:
Single-Arm, Non-Randomized, Time Series, Single-Subject Study. Observational study of the FMT intervention. Single subject studies are based on repeated observations within an individual over time and are acknowledged as an important research method for generating scientific evidence about the health or behavior of an individual. This design is desirable when the available patient pool is limited and thus it is not optimal to randomize participants to a control arm. The subject serves as his/her own control, rather than using another individual/group.These designs are used primarily to evaluate the effect of a variety of interventions in early stage clinical research development.
Other: Fecal Microbiota Transplantation (FMT)
Longitudinal FMT study: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Also known as: Taymount Clinic
Fecal microbial community structure and functional changes over six time frames for phylum, genus and species taxonomic level bacteria, virus, fungi, and archaea.
Shotgun Metagenomics
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Walking and balance changes over four time frames for stride time (seconds).
Orthopedic gait task, side gaze gait, and alternating gaze gait metrics.
Time frame: Baseline, 3 week, 13 week, 52 week
Walking and balance changes over four time frames for stride distance (meters).
Orthopedic gait task, side gaze gait, and alternating gaze gait metrics.
Time frame: Baseline, 3 week, 13 week, 52 week
Walking and balance changes over four time frames for cadence (total number of steps per minute).
Orthopedic gait task, side gaze gait, and alternating gaze gait metrics.
Time frame: Baseline, 3 week, 13 week, 52 week
Walking and balance changes over four time frames for step width (meters).
Orthopedic gait task, side gaze gait, and alternating gaze gait metrics.
Time frame: Baseline, 3 week, 13 week, 52 week
Walking and balance changes over four time frames for average pelvis forward velocity (meters per second).
Orthopedic gait task, side gaze gait, and alternating gaze gait metrics.
Time frame: Baseline, 3 week, 13 week, 52 week
Walking and balance changes over four time frames for pelvis smoothness (pelvis horizontal speed).
Orthopedic gait task, side gaze gait, and alternating gaze gait metrics.
Time frame: Baseline, 3 week, 13 week, 52 week
Fecal targeted short-chain-fatty-acid metabolomics concentration changes over six time frames for acetate (mM/kg), propionate (mM/kg), butyrate (mM/kg), and total SCFA (mM/kg).
Targeted metabolomics of short-chain-fatty-acids (SCFA).
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Measurement of blood serum biomarker brain-derived neurotrophic factor (BDNF) (ng/ml) changes over six time frames.
ELISA (enzyme-linked immunosorbent assay)
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Sleep changes over six time frames.
Munich ChronoType Questionnaire (MCTQ). Questions about work day and free day sleep schedules, work details, and lifestyle provide data to aid in the understanding of how biological clocks work in social life, such as Roenneberg's conclusions of social jetlag. The MCTQ categorizes each participant into one of seven chronotype groups, and utilizes data on participants' midsleep phase and sleep debt to survey what "type" of sleeper each person is.
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Food timing changes over six time frames.
Food Timing Screener (FTS) questionnaire. A structured food demographics questionnaire was therefore developed to access food timing. The questionnaire consists of eight questions asking subjects' eating habits on work days and non-work days. Questions include the time of the main meal during work and non-work days, time of last meal before bed, consistency of dinner within work and non-work days, and consistency of breakfast, lunch, and dinner between work and non-work days.
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Gastrointestinal symptoms changes over six time frames (t-scores, mean, standard deviations).
Patient-Reported Outcomes Measurements Information System (PROMIS) gastrointestinal questionnaire for Belly Pain (6 questions), Bowel Incontinence (4 questions), Constipation (9 questions), and Gas \& Bloating (12 questions). Higher score denoted more GI symptoms. Lower score denotes less GI symptoms. Scores range from 20 (low) to 80 (high). A score of 50 is denoted as the general population.
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Walking changes over six time frames.
Multiple sclerosis walking scale questionnaire. Higher scores indicate a greater impact from MS on walking than lower scores. Scale range from 1 (no impact) to 5 (high impact). 12 questions in total.
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Lesions changes over three time frames.
MRI of brain and spine
Time frame: Baseline, 26 week and 52 week
Food and frequency of consumption changes over six time frames.
Food Time Questionnaire (FTQ) consists of a list of foods and the frequency in which these foods are consumed in at each time frame.
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Single day food recall changes over six time frames.
Automated Self-Administered 24-Hour Recall (ASA24) Dietary Assessment. Total nutrients from all supplements reported in a given day.
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Diet changes over six time frames.
Vioscreen Food Frequency Questionnaire (FFQ). Total of 19 measured food components collected for each time frame. Vioscreen captures comprehensive dietary behaviors in just 30 minutes. VioScreen is a unique online dietary questionnaire, management and analysis system that efficiently gathers and manages data, that immediately identify dietary "habits" and counsel for lifestyle changes.
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Measurement of blood serum biomarker Interleukin-6 (IL-6) (pg/ml) changes over six time frames.
ELISA (enzyme-linked immunosorbent assay)
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Measurement of blood serum biomarker Interleukin-* (IL-8) (pg/ml) changes over six time frames.
ELISA (enzyme-linked immunosorbent assay)
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Measurement of blood serum biomarker Tumor necrosis factor alpha (TNFα) (pg/ml) changes over six time frames.
ELISA (enzyme-linked immunosorbent assay)
Time frame: Baseline, 3 week, 13 week, 26 week, 39 week, 52 week
Plan to share: Undecided — It is not yet known if there will be a plan to make IPD available. This pilot study of FMT in a patient with multiple sclerosis (MS) could suggest a potential effective treatment. More clinical trials (larger sample size) will be needed to study the potential of FMT for the treatment of MS and it's long term effects in the future.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Rush University Medical Center